Aquestive therapeutics, inc. announces closing of $8.5 million registered direct offering

Warren, n.j., june 08, 2022 (globe newswire) -- aquestive therapeutics, inc. (nasdaq: aqst), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, today announced that it has closed its previously announced registered direct offering with a single healthcare-focused institutional investor and certain of the company's executives, to purchase 8,850,000 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 8,850,000 shares of common stock at a purchase price per share (and accompanying warrant) of $0.96 for the institutional investor and $1.09 for the company's executives for gross proceeds of approximately $8.5 million. the warrants have a five-year term, are exercisable six months following the date of issuance and have an exercise price of $0.96 per share.
AQST Ratings Summary
AQST Quant Ranking